We are live on ! Find out more
QNRX

Quoin Pharmaceuticals

2 hedge funds and large institutions have $937K invested in Quoin Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more capital invested

Capital invested by funds: $630K → $937K (+$307K)

0% more ownership

Funds ownership: 0%0% (+0%)

33% less funds holding

Funds holding: 32 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.04%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$670K +$97.4K +1 +17%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$240K +$195K +2 New
Morgan Stanley
3
Morgan Stanley
New York
$22K
JP Morgan Chase
4
JP Morgan Chase
New York
$3K
HNB
5
Huntington National Bank
Ohio
$2K
Citadel Advisors
6
Citadel Advisors
Florida
-$60K -1 Closed
HF
7
HRT Financial
New York
-$48K -1 Closed
UBS Group
8
UBS Group
Switzerland
-$31K

QNRX Hedge Fund Activity: Q3 2021 in Review

2 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q3 2021, worth a combined $937K — up 49% from $630K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of QNRX and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $195K. The largest seller was Citadel Advisors, exiting entirely with an estimated $60K sold.

  • 2 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q3 2021, down from 3 in Q2 2021.
  • Funds reported $937K of Quoin Pharmaceuticals stock for Q3 2021, up 49% quarter-over-quarter.
  • 1 fund opened new Quoin Pharmaceuticals positions in Q3 2021 and 2 closed out, a net change of -1 holder.
  • The largest Quoin Pharmaceuticals buyer in Q3 2021 was Geode Capital Management, an estimated $195K added.
  • The largest Quoin Pharmaceuticals seller in Q3 2021 was Citadel Advisors, an estimated $60K sold.

Based on aggregated 13F filings for Q3 2021.